BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home
»
Newsletters
» BioWorld
BioWorld
May 6, 2009
View Archived Issues
Amylin Shares Jump on NDA but Drug Class Concerns Linger
San Diego-based Amylin has filed for regulatory approval of once weekly exenatide for diabetes, causing a slight jump in its shares and the shares of its partners, Alkermes and Eli Lilly and Co. (BioWorld Today)
Read More
Calistoga's Series B Adds $30M for p110 Delta PI3 Kinase Drugs
Read More
Three-Ingredient Cocktail Makes Heart Cells from Stem Cells
Read More
Anthera Hits Phase IIb Goals with SPLA2 Inhibitor for Acute ACS
Read More
Vernalis Raises £22M Offering Hefty Discount
Read More
Clinic Roundup
Read More
Other News To Note
Read More
